Illumina executives outlined progress on the company’s multiomics strategy at ASHG, saying roadmap technologies will be market‑ready next year as the firm integrates proteomics, single‑cell and spatial capabilities. CTO Steve Barnard described continued rollouts and planned upgrades intended to position Illumina across genomics and emerging omics verticals. Separately, Element Biosciences’ AVITI24 system was highlighted as a 2025 Top Innovation for enabling multiomic data generation from a single sample and single run—an advance aimed at labs pursuing integrated genomic, epigenomic and transcriptomic assays. Vendors are positioning instrument and chemistry upgrades to capture a share of growing multiomics demand. For platform buyers and service labs, these moves signal intensified competition in end‑to‑end multiomics workflows and reinforce the importance of reagent and software integration for large‑scale studies and clinical applications.